文献速递肺栓塞与肺血管病

急性症状性肺栓塞再通术的疗效与安全性:系统评价与网状Meta分析

Efficacy and safety outcomes of recanalisation procedures in patients with acute symptomatic pulmonary embolism: systematic review and network meta-analysis.
PubMed 文献 · Thorax · 2017-11-13

该系统评价与网状Meta分析检索多个数据库至2015年7月,纳入比较再通术与抗凝治疗的随机临床试验,评估急性症状性肺栓塞患者的疗效与安全性。结果显示再通术与抗凝相比在全因死亡率上无显著差异,但全剂量溶栓增加大出血风险;低剂量溶栓死亡与出血概率最低。

要点

  • 再通术与抗凝治疗在全因死亡率上无显著差异。
  • 全剂量溶栓相比抗凝增加大出血风险(OR 2.00,95%CI 1.06–3.78)。
  • 低剂量溶栓死亡与大出血概率最低。

核心结论

  • 在肺栓塞治疗中,再通术与标准抗凝相比未见明显优势。
  • 低剂量溶栓与最低的死亡和大出血概率相关。

研究设计与样本

  • 系统评价与网状Meta分析,检索PubMed、Cochrane Library、EMBASE、EBSCO、Web of Science和CINAHL数据库至2015年7月31日。
  • 纳入比较再通术彼此或与抗凝治疗的随机临床试验,患者诊断为肺栓塞。

主要发现

  • 全因死亡率:全剂量溶栓 vs 抗凝 OR 0.60(95%CI 0.36–1.01);低剂量溶栓 OR 0.47(95%CI 0.14–1.59);导管相关溶栓 OR 0.31(95%CI 0.01–7.96)。
  • 全剂量溶栓相比抗凝增加大出血风险:OR 2.00(95%CI 1.06–3.78)。
  • 死亡概率最低为导管导向溶栓(SUCRA 0.67),其次低剂量溶栓(SUCRA 0.66)和全剂量溶栓(SUCRA 0.55)。
  • 大出血概率最低为低剂量溶栓(SUCRA 0.61),其次导管导向溶栓(SUCRA 0.54)和全剂量溶栓(SUCRA 0.17)。
  • 仅纳入血流动力学稳定肺栓塞患者的敏感性分析结果相似。

临床怎么用

  • 再通术不宜常规替代抗凝治疗,需个体化评估获益与出血风险。
  • 若选择溶栓,低剂量方案可能与更低的死亡和大出血概率相关。

局限性

  • 检索截止2015年7月31日,未纳入此后发表的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to review the efficacy and safety of recanalisation procedures for the treatment of PE. METHODS: We searched PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science and CINAHL databases from inception through 31 July 2015 and included randomised clinical trials that compared the effect of a recanalisation procedure versus each other or anticoagulant therapy in patients diagnosed with PE. We used network meta-analysis and multivariate random-effects meta-regression to estimate pooled differences between each intervention and meta-regression to assess the association between trial characteristics and the reported effects of recanalisation procedures versus anticoagulation. RESULTS: For all-cause mortality, there were no significant differences in event rates between any of the recanalisation procedures and anticoagulant treatment (full-dose thrombolysis: OR 0.60; 95% CI0.36 to 1.01; low-dose thrombolysis: 0.47; 95% CI 0.14 to 1.59; and catheter-associated thrombolysis: 0.31; 95% CI 0.01 to 7.96). Full-dose thrombolysis increased the risk of major bleeding (2.00; 95% CI 1.06 to 3.78) compared with anticoagulation. Catheter-directed thrombolysis was associated with the lowest probability of dying (surface under the cumulative ranking curve (SUCRA), 0.67), followed by low-dose thrombolysis (SUCRA, 0.66) and full-dose thrombolysis (SUCRA, 0.55). Similarly, low-dose thrombolysis was associated with the lowest probability of major bleeding (SUCRA, 0.61), followed by catheter-directed thrombolysis (SUCRA, 0.54) and full-dose thrombolysis (SUCRA, 0.17). The results were similar in sensitivity analyses based on restricting only to studies in haemodynamically stable patients with PE. CONCLUSIONS: In the treatment of PE, recanalisation procedures do not seem to offer a clear advantage compared with standard anticoagulation. Low-dose thrombolysis was associated with the lowest probability of dying and bleeding. TRIAL REGISTRATION NUMBER: PROSPERO CRD42015024670.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Jimenez D, Martin-Saborido C, Muriel A, et al. Efficacy and safety outcomes of recanalisation procedures in patients with acute symptomatic pulmonary embolism: systematic review and network meta-analysis. Thorax. 2017. PMID: 29133351. doi:10.1136/thoraxjnl-2017-210040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。